STING agonist PF-07820435

{
  "id": "MLC-T-ONC-016884",
  "term": "STING agonist PF-07820435",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable agonist of the intracellular innate immune adaptor stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon oral administration, STING agonist PF-07820435 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sting-agonist-pf-07820435/"
}